Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.BTX · Entity 6045 | Director | July 01, 2017 | July 06, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date July 01, 2017 · Filed July 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2022-06-30 | Direct | 20,000 |
Reported balance
After 2017-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-01 · Grant · Acquired 20,000 · Balance 20,000 F2: Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors. |
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2021-06-30 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2017-07-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 20,000 F3: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016. |
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $3.57 · Expires 2020-06-30 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2017-07-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 20,000 F4: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015. |
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $3.11 · Expires 2019-06-30 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2017-07-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 20,000 F5: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014. |
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $2.86 · Expires 2019-04-10 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2017-07-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 20,000 F6: Became exercisable in four equal quarterly installments after the date of grant on April 11, 2014. |
| Common Shares, no par valueSEC Table I · non-derivative | Indirectsee footnote | 32,050 |
Reported balance
Holding disclosure · report date 2017-07-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 32,050 F1: All shares are owned by Schlachet Management Ltd., a privately held company of which Mr. Schlachet is the sole shareholder, chief executive officer, and director. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares are owned by Schlachet Management Ltd., a privately held company of which Mr. Schlachet is the sole shareholder, chief executive officer, and director.
F2: Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors.
F3: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.
F4: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.
F5: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.
F6: Became exercisable in four equal quarterly installments after the date of grant on April 11, 2014.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2017 Filed Jul 6, 2017 00:22 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 20,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-17-043813 · doc4.xml · derivative · entry 2 SCHLACHET DAVID · CIK 0001235445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2022-06-30 F2 · derivative.exercise_date: Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.